Company news

Annexon, Inc. news in 2022

Annexon, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023

November 2, 2022

Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

July 10, 2022

Annexon Announces $130 Million Private Placement Financing

July 7, 2022

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

June 6, 2022

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

May 8, 2022

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

April 6, 2022

Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022

March 2, 2022

Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors

January 19, 2022

Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

January 3, 2022

Decks in 2022